Halozyme Therapeutics Inc
NASDAQ:HALO
Halozyme Therapeutics Inc
EPS (Diluted)
Halozyme Therapeutics Inc
EPS (Diluted) Peer Comparison
Competitive EPS (Diluted) Analysis
Latest Figures & CAGR of Competitors
Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
EPS (Diluted)
$2
|
CAGR 3-Years
31%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
EPS (Diluted)
$3
|
CAGR 3-Years
6%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
3%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
EPS (Diluted)
$0
|
CAGR 3-Years
18%
|
CAGR 5-Years
-39%
|
CAGR 10-Years
-18%
|
|
Amgen Inc
NASDAQ:AMGN
|
EPS (Diluted)
$7
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
1%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
EPS (Diluted)
$15
|
CAGR 3-Years
13%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
EPS (Diluted)
$33
|
CAGR 3-Years
-3%
|
CAGR 5-Years
10%
|
CAGR 10-Years
25%
|
See Also
What is Halozyme Therapeutics Inc's EPS (Diluted)?
EPS (Diluted)
2.5
USD
Based on the financial report for Mar 31, 2024, Halozyme Therapeutics Inc's EPS (Diluted) amounts to 2.5 USD.
What is Halozyme Therapeutics Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 3Y
31%
Over the last year, the EPS (Diluted) growth was 90%. The average annual EPS (Diluted) growth rates for Halozyme Therapeutics Inc have been 31% over the past three years .